Jack joined SV in 2019 and is an Associate in the Biotech team. He helps form and fund companies developing transformational new medicines. Jack serves as a board observer at Pionyr Immunotherapeutics, Caraway Therapeutics and Catamaran Bio. He has helped SV invest in Xilio Therapeutics, as well as incubate and launch Catamaran Bio.
Charles carries out due diligence of new deals, and provides strategic, BD, and operational support to existing companies in the SV portfolio supporting them in bringing drugs from discovery to market.
Prior to joining SV, Jack was a Senior Analyst at ClearView Healthcare Partners, where he evaluated commercial opportunities to support product launch, portfolio optimization, and acquisitions for leading life sciences companies. He also played a role in the founding of the company’s analytics practice. Prior to ClearView, Jack worked within or consulted for Amicus Therapeutics, Sage Products, and MC10.
Outside of SV Jack is a proud Minnesotan who enjoys returning home to play outdoor hockey whenever possible.
BA, Chemistry and Economics, College of the Holy Cross; MS, Engineering, Science and Technology Entrepreneurship, University of Notre Dame